TCR-engineered, customized, antitumor T cells for cancer immunotherapy: Advantages and limitations

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 121-129

  Chhabra, Arvind ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer; Immunotherapy; MHC class I TCR engineered CD4 T cells; TCR engineering

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL DEATH; EFFECTOR CELL; ENGINEERING; EX VIVO STUDY; HOMEOSTASIS; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; NONHUMAN; REVIEW; T LYMPHOCYTE; TECHNOLOGY;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 79551487389     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2011.10     Document Type: Review

References (40)

1. Rosenberg, S.A., Yang, J.C., and Restifo, N.P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
2. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature 411, 380-384.
3. Finn, O.J. (2008) Cancer immunology. N. Engl. J. Med. 358, 2704-2715.
4. Whiteside, T.L. (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912.
5. Grimm, E.A., Mazumder, A., Zhang, H.Z., and Rosenberg, S.A. (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841.
6. Rosenberg, S.A., Spiess, P., and Lafreniere, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321.
7. Yee, C., Thompson, J.A., Byrd, D., Riddell, S.R., Roche, P., Celis, E., and Greenberg, P.D. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A. 99, 16168-16173.
8. Abken, H., Hombach, A., Reinhold, U., and Ferrone, S. (1998) Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol. Today 19, 2-5.
9. Eshhar, Z., Bach, N., Fitzer-Attas, C.J., Gross, G., Lustgarten, J., Waks, T., and Schindler, D.G. (1996) The T-body approach: potential for cancer immunotherapy. Springer Semin. Immunopathol. 18, 199-209.
10. Sadelain, M. (2009) T-cell engineering for cancer immunotherapy. Cancer J. 15, 451-455.
11. Haynes, N.M., Trapani, J.A., Teng, M.W., Jackson, J.T., Cerruti, L., Jane, S.M., Kershaw, M.H., Smyth, M.J., and Darcy, P.K. (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100, 3155-3163.
12. Maher, J., Brentjens, R.J., Gunset, G., Riviere, I., and Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20, 70-75.
13. Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., Forman, S.J., Gopal, A.K., Pagel, J.M., Lindgren, C.G., Greenberg, P.D., Riddell, S.R., and Press, O.W. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271.
14. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., Chen, C.C., Yang, J.C., Rosenberg, S.A., and Hwu, P. (2006) A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
15. Dembic, Z., Haas, W., Weiss, S., McCubrey, J., Kiefer, H., von Boehmer, H., and Steinmetz, M. (1986) Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320, 232-238.
16. Cole, D.J., Weil, D.P., Shamamian, P., Rivoltini, L., Kawakami, Y., Topalian, S., Jennings, C., Eliyahu, S., Rosenberg, S.A., and Nishimura, M.I. (1994) Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 54, 5265-5268.
17. Heemskerk, M.H., Hoogeboom, M., Hagedoorn, R., Kester, M.G., Willemze, R., and Falkenburg, J.H. (2004) Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199, 885-894.
18. Willemsen, R., Ronteltap, C., Heuveling, M., Debets, R., and Bolhuis, R. (2005) Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Gene Ther. 12, 140-146.
19. Chhabra, A. (2009) MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy. Endocr. Metab. Immune Disord. Drug Targets 9, 344-352.
20. Zhao, Y., Zheng, Z., Robbins, P.F., Khong, H.T., Rosenberg, S.A., and Morgan, R.A. (2005) Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415-4423.
21. Morgan, R.A., Dudley, M.E., Yu, Y.Y., Zheng, Z., Robbins, P.F., Theoret, M.R., Wunderlich, J.R., Hughes, M.S., Restifo, N.P., and Rosenberg, S.A. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171, 3287-3295.
22. Cooper, L.J., Kalos, M., Lewinsohn, D.A., Riddell, S.R., and Greenberg, P.D., (2000) Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74, 8207-8212.
23. Keene, J.A. and Forman, J. (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155, 768-782.
24. Bevan, M.J. (2004) Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4, 595-602.
25. Pardoll, D.M. and Topalian, S.L. (1998) The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594.
26. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., and Levitsky, H. (1998) The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368.
27. Mumberg, D., Monach, P.A., Wanderling, S., Philip, M., Toledano, A.Y., Schreiber, R.D., and Schreiber, H. (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. U. S. A. 96, 8633-8638.
28. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M.H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P.Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P.G., van der Bruggen, P., and Boon, T. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80, 219-230.
29. Toes, R.E., Ossendorp, F., Offringa, R., and Melief, C.J. (1999) CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756.
30. Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A., and Yee, C. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703.
31. Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E.L., Lane, M., Kwon, E.K., Muranski, P., Restifo, N.P., and Antony, P.A. (2010) Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207, 651-667.
32. Quezada, S.A., Simpson, T.R., Peggs, K.S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P.A., Restifo, N.P., and Allison, J.P. (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207, 637-650.
33. Chhabra, A., Yang, L., Wang, P., Comin-Anduix, B., Das, R., Chakraborty, N.G., Ray, S., Mehrotra, S., Yang, H., Hardee, C.L., Hollis, R., Dorsky, D.I., Koya, R., Kohn, D.B., Ribas, A., Economou, J.S., Baltimore, D., and Mukherji, B. (2008) CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J. Immunol. 181, 1063-1070.
34. Ray, S., Chhabra, A., Mehrotra, S., Chakraborty, N.G., Ribas, A., Economou, J., and Mukherji, B. (2009) Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin. Dermatol. 27, 603-613.
35. Ahmed, N. and Gottschalk, S. (2009) How to design effective vaccines: lessons from an old success story. Expert Rev. Vaccines 8, 543-546.
36. Makedonas, G. and Betts, M.R. (2006) Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin. Immunopathol. 28, 209-219.
37. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., Zheng, Z., Nahvi, A., de Vries, C.R., Rogers-Freezer, L.J., Mavroukakis, S.A., and Rosenberg, S.A. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
38. Bendle, G.M., Linnemann, C., Hooijkaas, A.I., Bies, L., de Witte, M.A., Jorritsma, A., Kaiser, A.D., Pouw, N., Debets, R., Kieback, E., Uckert, W., Song, J.Y., Haanen, J.B., and Schumacher, T.N. (2010) Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565-570, 1p following 570.
39. Chhabra, A. (2010) Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy. Vaccine 28, 4566-4572.
40. Tanne, J.H. (2010) FDA approves prostate cancer "vaccine". BMJ 340, c2431.